TraviaTechPie Review

The Setup

Walk into a smartwatch demo and three words appear on every box: ECG. Heart rate. Blood pressure. Three cardiovascular measurements on one wrist, marketed as one feature set. The implication is that they belong together — all three are “heart monitoring,” all three are “FDA cleared somewhere,” all three are part of the modern smartwatch deal.

The implication is wrong.

These three features have radically different accuracy profiles. One of them is genuinely clinical-grade. One is reliable in some conditions and unreliable in others. One is marketed in ways the science does not yet support. And the gap between the three is much larger than any review’s “Yes/No” column suggests.

This piece is the deep dive on cardiovascular monitoring — the second piece in our health-features cluster (see the three-tier pillar for where each feature sits in the broader map). The thesis here is sharper:

ECG is what the wrist does best. Heart rate is what the wrist does well only sometimes. Blood pressure is what the wrist mostly cannot do — and the marketing has gotten ahead of the science.

Let’s walk through each, with the actual numbers.

Part 1 — ECG: the one feature where the wrist meets the clinic

ECG is the strongest cardiovascular measurement available on a smartwatch in 2026. Not just “good for a wearable” — actually clinically meaningful. The reason is worth understanding.

### What ECG actually measures

A smartwatch ECG records a single-lead Lead I ECG. You touch the bezel, crown, or sensor on the case for 30 seconds, completing an electrical circuit between your left arm (the watch on your wrist) and your right arm (your finger touching the bezel). The watch records the electrical signal of your heart’s depolarization-repolarization cycle and produces a single-lead waveform.

A clinical 12-lead ECG records 12 different electrical perspectives. A single-lead is one perspective. It is enough to detect atrial fibrillation (AFib) reliably. It is not enough to localize a heart attack, identify the specific origin of a complex arrhythmia, or replace a clinical workup.

### The accuracy numbers

Two separate validation efforts are worth distinguishing — they get conflated in most coverage.

Apple ECG app, FDA De Novo submission data (the 30-second active ECG reading): – AFib detection sensitivity: 98.3% in classifiable recordings – Sinus rhythm specificity: 99.6% – Classifiability rate: 87.8% of recordings (the rest came back as inconclusive)

Apple Heart Study (Stanford, 419,297 participants, published in NEJM 2019) — a different study evaluating the passive PPG-based irregular rhythm notification, not the active ECG app: – Positive predictive value of an irregular pulse notification: 84% (84% of users who received an alert and completed follow-up ECG patch testing had AFib confirmed)

So there are two signals, two validation paths. The active ECG reading is what the 98.3%/99.6% numbers describe. The passive notification is what the 84% PPV describes. Both are clinically meaningful in different ways.

Galaxy Watch ECG validation (Samsung internal + Korea FDA submission data): – Sensitivity: 90–96% – Specificity: 95%+

Withings ScanWatch and Kardia mobile ECG (related but different category): similar 90%+ sensitivity profiles.

These are not “wearable-grade” numbers. They are screening-tool numbers, comparable to many primary-care screening tests. The difference between a smartwatch ECG and a 12-lead clinical ECG is what you can do with the result — the smartwatch result is a yes/no AFib screen, the clinical 12-lead is a full diagnostic study.

### What ECG cannot do

The smartwatch ECG limitations matter as much as its strengths.

It catches one rhythm reliably (AFib) and misses the rest. Atrial flutter, supraventricular tachycardia, ventricular ectopy, AV blocks — the watch is either silent on these or unreliable. AFib is the most clinically important arrhythmia to screen for in the general population (stroke risk), so this is not a critical gap, but it is a real one.

It does not diagnose heart attacks. A single Lead I cannot show ST-segment elevation in the territories that matter for myocardial infarction. If you have crushing chest pain, the watch is not the answer. The hospital is.

False positives exist. Cold extremities, recent exercise, tremor, poor sensor contact all produce false irregular-rhythm flags. The watches handle this conservatively (they ask for retries, they flag readings as inconclusive), but a user-facing false positive can still cause anxiety.

It requires user action. A 30-second reading, manual start, finger on the bezel. Background monitoring of irregular pulse notifications happens continuously and silently — but a confirmed ECG reading requires you to take it. Some watches have introduced passive AFib detection (Apple’s Irregular Rhythm Notification feature, Samsung’s similar feature) that runs in the background using PPG (the optical sensor), but those notifications still need an ECG confirmation read to be diagnostic.

That last point is worth restating. There are two distinct features here: passive PPG-based irregular-rhythm notifications (always running, less specific) and active ECG readings (30-second, more specific). The screening flow is — passive alerts you to a possible irregularity, active reading confirms it. Both Apple and Samsung use this two-step model. Garmin Venu 4, Pixel Watch, Fitbit, Huawei follow the same pattern.

### Brand-by-brand ECG implementation

The hardware difference between brands is smaller than the marketing implies. They all use single-lead Lead I configurations. The differences are in user experience and which models have it.

A few things worth noting in this table.

Huawei has CE but no US FDA. The hardware works, the algorithm is validated to European standards, but the regulatory pathway for the US has not been pursued. For a Korean reader this matters in two ways: domestic use is fine, but if you travel and a US clinician wants to interpret the trace, the chain-of-evidence is weaker.

Whoop MG is FDA-cleared, Whoop 5.0 is not. This is one of the most misunderstood points in this category. The Whoop Life subscription gives you the MG hardware (with ECG); the One and Peak subscriptions give you the 5.0 hardware (no ECG sensor at all). If ECG is your purchase reason, you must subscribe to Life ($359/year) — and the device is a different physical product, not a software unlock. We covered this in detail in the Whoop deep dive.

Garmin’s ECG is newer. Garmin entered the ECG space later than Apple/Samsung, and it is available on a smaller subset of models (Venu 4 and higher-tier Forerunner/Fenix). If you are a runner who specifically needs ECG, the Garmin lineup splits — Venu 4 has it, Forerunner 265/970 has it on newer firmware, but cheaper Forerunner models (165, 265, 570) do not.

### When ECG actually matters for purchase

Practical reframe. ECG matters as a purchase factor in a narrow set of situations.

1. Family history of AFib or stroke. Background AFib screening adds genuine value. Pick any brand with FDA-cleared ECG. 2. Age 65+ or known cardiovascular risk factors. AFib prevalence climbs with age. ECG screening is reasonable. 3. Episodic palpitations you want to document. A handheld ECG reading during an episode is more useful to your doctor than a description. The watch is faster than a clinic visit.

If none of those apply, ECG presence is not a strong differentiator. Almost every flagship smartwatch has it now. The Fitbit Charge 6 has it at $99 street. The race to the bottom on ECG is over — the feature is in everything serious.

Part 2 — Optical heart rate: accurate in conditions, less accurate in others

Smartwatch heart rate comes from photoplethysmography (PPG): green LEDs illuminate the skin, photodiodes measure the light reflected back, and pulse rhythm is extracted from the rhythm of capillary blood-volume changes. The technology is mature. It is also conditional.

### The accuracy numbers, by condition

Validated against a chest-strap ECG (the practical gold standard outside a lab):

• Resting / sitting / sleeping: ±1–3 bpm. Effectively as accurate as a clinical pulse oximeter for HR.
• Steady-state walking, easy jogging: ±3–5 bpm. Reliable.
• Moderate-intensity steady cardio (Zone 2/3): ±5–8 bpm. Usable for training zones but not for precise interval work.
• High-intensity intervals (Zone 4–5, sprints, HIIT): ±10–15 bpm. The wrist consistently under-reads during peak intensity, with a lag of 5–15 seconds catching up to actual HR.
• Weight training, gripping, push-ups: Often fails. Wrist tension and constant muscle contraction disrupt the optical signal. Many readings are simply missing.
• Cycling with hands on handlebars: Similar to weight training. Optical signal disrupted.
• Cold conditions (below ~10°C / 50°F): Reduced peripheral blood flow degrades signal. 5–10 bpm under-read common.
• Dark skin tones: Documented and unresolved accuracy degradation. Multiple validation studies show 2–4 bpm higher error rates compared to light skin tones, and AFib detection sensitivity drops several percentage points. The industry response has been incremental sensor refinement, not a solved problem.

This is the honest picture. Smartwatch optical HR works very well for resting heart rate, sleep heart rate, walking, and easy aerobic activity. It works less well for intervals, lifting, cycling, and cold conditions. For serious training, a chest strap is still the right answer if HR data feeds your training decisions.

### Why the “average HR” looks better than it is

A common misconception: “My watch averaged 152 bpm for my run, and the strap averaged 154 bpm. So the watch is accurate.” The problem is that average smooths over what matters. The actual recording often looks like this:

• Strap: continuous, every-second reading, 152 bpm peak in the third interval
• Watch: missed the first 20 seconds of every interval, under-read by 15 bpm during the surges, eventually caught up. Average comes out close because the over-reads and under-reads partially cancel.

If you train by precise HR zones, the watch’s lag during transitions is a real cost. If you train by perceived effort and use HR as a daily summary, the lag is invisible.

### Resting HR over time — the metric that almost always works

The single most useful HR metric from a smartwatch is resting heart rate trend over weeks. Measured overnight or at first wake, smartwatch resting HR is extremely accurate (it’s the easy condition for PPG). And the trend signals everything from training adaptation (resting HR drops with aerobic fitness) to illness onset (resting HR jumps 5–10 bpm 24–48 hours before symptoms — well documented across multiple studies).

This is where smartwatch HR earns its keep regardless of brand. Apple’s Vitals, Samsung’s My Health, Garmin’s Body Battery, Fitbit’s Daily Readiness, Whoop’s Recovery all rely on it. The brand differences in implementation are small. The signal is solid across the board.

Part 3 — Blood pressure: where the marketing has outrun the science

This is the most fraught section of the cardiovascular feature set. Wrist-based blood pressure measurement is the area where marketing claims have moved fastest and clinical validation has moved slowest.

### What “blood pressure on a smartwatch” actually means

Three different things, sold under similar names.

1. Samsung Galaxy Watch BP (true measurement claim, with caveats). Available on Galaxy Watch 3 and later, restricted by region (Korea, Europe, parts of Asia — not US for measurement). Uses pulse-wave analysis to estimate systolic/diastolic BP. Requires monthly recalibration against a real upper-arm cuff — without recalibration, drift makes readings progressively unreliable. US FDA has not cleared this as a measurement. The Korean MFDS (Ministry of Food and Drug Safety) has cleared it as a Class II medical device for trend monitoring.

What does the validation literature say? Independent studies show wrist pulse-wave BP estimation correlates with cuff BP at population level, but individual readings drift by 5–10 mmHg or more between recalibrations. As a population screening tool, it has signal. As a personal measurement, the cuff is more accurate.

2. Apple Watch Hypertension Notification (notification claim, FDA-cleared). Apple received FDA clearance on September 11, 2025, debuting alongside Apple Watch Series 11. The feature itself runs on Apple Watch Series 9, Series 10, Series 11, Ultra 2, Ultra 3, and SE 3 with watchOS 26 — not a Series 11 exclusive. It analyzes vascular response patterns over 30-day windows using the optical sensor and notifies users who may have hypertension. Apple explicitly does not call this a measurement. The FDA clearance is for the notification feature — flagging at-risk individuals to seek clinical BP measurement — not for blood pressure measurement itself. Apple’s published validation (clinical study of over 2,000 participants, training data from 100,000+) shows the notification detects roughly half of clinically hypertensive individuals (false-negative rate around 50%, meaning many hypertensive users will not be flagged). False-positive rate is lower (the system errs toward not flagging non-hypertensive users).

The honest framing is that the Apple feature is an early-warning trigger to go get tested, not a substitute for a real BP measurement. Apple’s own UX explicitly directs users to confirm with a cuff.

3. Whoop MG overnight BP estimate (beta, Life subscription only). Estimates overnight BP using PPG-derived pulse transit time. Currently beta. Limited published validation. Not FDA-cleared as a measurement.

### What this looks like compared to a real cuff

The honest comparison.

A $50 upper-arm cuff (Omron, A&D, Withings BPM Connect) measures BP using oscillometric methodology — the same approach used in primary care offices. Accuracy when calibrated and used correctly: ±3 mmHg in clinical validation studies. This is the reference standard for at-home BP monitoring, endorsed by every major cardiology society.

A $400+ smartwatch with BP features achieves at best ±5–8 mmHg with monthly recalibration (Samsung) or detects approximately half of hypertensive cases as a notification (Apple). The watch is more convenient. The cuff is more accurate. The gap is not close.

The pragmatic recommendation has not changed in years: if you care about blood pressure, buy a $50 cuff regardless of which watch you wear. The watch feature, when present, is a convenience layer on top — useful for “is this trending up?” awareness, not for the actual measurement that informs medical decisions.

### Why the marketing leads the science

Worth a brief note on why this category looks the way it does. Blood pressure has the largest cardiovascular health audience — roughly 1 in 3 adults globally has hypertension, and the market for at-home monitoring is enormous. The first brand to credibly claim “blood pressure on a smartwatch” wins a marketing battle worth billions. The clinical validation work required to genuinely deliver that claim is slow, expensive, and ongoing. So the marketing leads — and the regulatory bodies catch up by parsing “notification” vs “measurement” labels carefully.

This is not a permanent state. Multi-wavelength PPG, ultrasound-based wrist BP sensors, and tonometric approaches are all in research and development. In five years, wrist BP measurement may genuinely approach cuff accuracy. In 2026, it does not.

Part 4 — The Master Comparison Table

Where the seven major brands stand on each cardiovascular feature.

A few things to surface from this matrix.

ECG is essentially commoditized. Every flagship has it. The differentiation is not “does it have ECG” but “does it have FDA + CE for global validation, or only one.” Huawei’s CE-only status is the cleanest gap.

Heart rate accuracy is roughly tied at rest and roughly tied during intervals. Whoop and Garmin pull slightly ahead during high-intensity work, attributable to algorithm tuning for athletic populations. For the general user, the difference is invisible.

Blood pressure is where the brands genuinely diverge. Samsung makes the most aggressive measurement claim with monthly recalibration baggage. Apple takes the more conservative “notification” route with FDA approval. Whoop’s beta is a different category (overnight, sleep-context). Pixel Watch, Garmin, Fitbit, Huawei do not enter this space at all on the wrist — a conservative choice that, in light of the accuracy data, looks justifiable rather than missing.

The Buyer’s Question — re-framed for cardiovascular monitoring

The practical question is not “which watch has all three.” It is closer to three separate questions.

1. Do I need ECG screening?

If yes (family history, age, risk factors, episodic palpitations) — any FDA-cleared option works. Apple Watch, Galaxy Watch, Pixel Watch, Garmin Venu 4, Fitbit Charge 6, Whoop MG. The differences are small. Pick on overall watch fit. Note that Huawei is CE-only — fine for personal use, weaker if you want US clinical interpretation.

For brand-specific buying advice, see the Apple Watch buy guide, the Galaxy Watch buy guide, and the Garmin buy guide. The Fitbit lineup is covered in the Fitbit buy guide.

2. What kind of heart-rate data do I need?

If you train by precise HR zones and intervals — buy a chest strap regardless of watch brand. Wrist optical HR is not adequate for that use case from any brand.

If you train by perceived effort and want HR as daily context — every flagship works. The differences are marketing-level, not measurement-level.

If you want resting HR trends (illness early warning, training adaptation) — every flagship works equally well here. This is PPG’s strongest condition.

3. Do I need blood pressure on the wrist?

Short answer: no. Buy a $50 Omron cuff. It will be more accurate than any wrist-based feature.

Longer answer: if you want a wrist-based BP feature as supplementary context, the Galaxy Watch (in countries where it has measurement clearance) or the Apple Watch (for the Hypertension Notification, which is a different feature) are the two options. Recognize what you are getting. Neither replaces the cuff for actual measurement.

What’s Next in This Cluster

This piece covers the cardiovascular monitoring section of the broader health-features map. The next piece (A-3) deep dives into sleep tracking — where smartwatch sleep stages, sleep apnea detection (the only Tier 1 feature beyond ECG and heart rate), and sleep score implementations differ across brands. After that, A-4 on stress/HRV, A-5 on GPS accuracy, A-6 on SpO2 and respiratory monitoring, A-7 on recovery and VO2 max, and A-8 on the remaining features.

For the broader map of where each feature sits in the three-tier framework, return to the pillar piece. For model-level decisions rather than feature theory, see the five-part Apple vs Samsung vs Garmin comparison and the budget alternatives guide.

The Takeaway

Smartwatch cardiovascular monitoring is three different things with three different reliability profiles, sold together as one feature set.

ECG works. Single-lead Lead I, 98%+ sensitivity for AFib detection, FDA-cleared on every major flagship. The cleanest example of the wrist meeting the clinic. The differentiation between brands is small at this point — the question is whether you need ECG screening, not which ECG to buy.

Optical heart rate works conditionally. Resting and steady-state cardio is essentially solved. Intervals, lifting, cold conditions, and dark skin tones have documented accuracy gaps. The resting-HR trend over time is the most useful metric the wrist produces; the single workout-HR reading during sprints is the least useful.

Wrist blood pressure does not yet work the way the box implies. Samsung’s measurement requires monthly recalibration and lacks US FDA clearance. Apple’s Hypertension Notification is FDA-cleared as a notification, not a measurement, and misses about half of hypertensive cases. The $50 Omron cuff remains more accurate than any wrist-based feature.

If you internalize one rule from this piece: the three features do not deserve to be in the same column of the comparison table. They have radically different accuracy profiles, validation depth, and clinical utility. Treating them as one bullet point is the most common analytical mistake in the smartwatch space.

### Buy on Amazon

• Apple Watch Series 11 — ECG + Hypertension Notification (FDA)
• Galaxy Watch 8 — ECG (FDA) + BP measurement (Korea/EU)
• Pixel Watch 4 — ECG (FDA), no BP
• Garmin Venu 4 — ECG (FDA), no BP
• Fitbit Charge 6 — ECG (FDA) at $99, no BP

As an Amazon Associate I earn from qualifying purchases.

Photo: Joshua Chehov / Unsplash